INSD OTC
Instadose Pharma Corp.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: -90.9%
3Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$462K
-1700.8% ▼
Net Income
-$589K
-1668.1% ▼
EPS (Diluted)
$-0.00
-1500.0% ▼
EBITDA
-$100K
-1700.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $4K | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | -100.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $2K | $0 | $0 | $0 |
| Gross Profit | $0 | $2K | $0 | $0 | $0 |
| Gross Margin | — | 49.1% | — | — | — |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $32K | $33K | $31K | $33K | $589K |
| Operating Expenses | $41K | $25K | $31K | $26K | $462K |
| Operating Income | -$32K | -$24K | -$23K | -$26K | -$462K |
| Operating Margin | — | -653.0% | — | — | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$41K | -$31K | -$23K | -$26K | -$462K |
| Tax Expense | -$170K | $0 | $0 | $0 | $0 |
| Net Income | -$41K | -$31K | -$39K | -$33K | -$589K |
| Net Margin | — | -867.0% | — | — | — |
| EPS (Diluted) | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| EBITDA | -$32K | -$31K | -$23K | -$6K | -$100K |
| Shares Outstanding | 75M | 75M | 75M | 75M | 75M |